Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1711)
  2. Journal Article (1446)
  3. Review (84)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (11)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3406)
  2. Solid Tumor Oncology Division (3406)
  3. GSK Faculty (1075)
  4. Department of Pathology and Laboratory Medicine (821)
  5. Hematology-Oncology Fellows (715)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (664)

More Groups

People
  1. Mark Kris (873)
  2. Alexander Drilon (639)
  3. Gregory Riely (606)
  4. Charles Rudin (497)
  5. Marc Ladanyi (419)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (126)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (704)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (159)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (90)

More Publications

Publishers
  1. American Society of Clinical Oncology (783)
  2. Elsevier Inc. (741)
  3. American Association for Cancer Research (387)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (80)

More Publishers

Results (3406)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dual Targeting of RET and SRC to Treat RET-Positive Non-Small Cell Lung Cancer
    Meeting Abstract

    Son, J.; Rix, L. L. R.; Fang, B.; Welsh, E. A.; Drilon, A.; Koomen, J. M.; Cocco, E.; Rix, U.
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Punekar, S. R.; Hong, D. S.; Luo, J.; Ou, S. H. I.; Johnson, M. L.; Spira, A.; Garrido-Laguna, I.; Goldman, J. W.; Herzberg, B.; Saltos, A.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Chemo-immunotherapy for borderline resectable and unresectable NSCLC
    Meeting Abstract

    Cappuzzo, F.; Landi, L.; Garbo, E.; Cooper, A.; Wang, X.; Mayoral, M.; Ginsberg, M. S.; Sholl, L.; Nishino, M.; Bott, M.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Phase I study of patritumab deruxtecan (HER3-DXd) in patients (pts) with advanced KRAS G12C non-small cell lung cancer (NSCLC): Study U102 cohort 5
    Meeting Abstract

    Paz-Ares, L.; Steuer, C.; Ruiter, G.; Nishio, M.; Murakami, H.; Kim, D. W.; Felip, E.; Baik, C. S.; Lin, C. C.; Massarelli, E.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7
    Meeting Abstract

    Passaro, A.; Girard, N.; Rodriguez Abreu, D.; Gumus, M.; Wu, Y. L.; Syrigos, K.; Ramlau, R.; Santos, E.; Berz, D.; Gandhi, C.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy outcomes of larotrectinib by prior therapy and performance status in patients with TRK fusion lung cancer
    Meeting Abstract

    Moreno Garcia, V.; Drilon, A.; Kummar, S.; Lin, J. J.; Tan, D. S. W.; Rieke, D. T.; Dubashi, B.; Kunhiparambath, H.; Burcoveanu, D. I.; Neu, N.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes
    Meeting Abstract

    Mazieres, J.; Veillon, R.; Cortot, A.; Ferrara, R.; Felip, E.; Garassino, M.; Le, X.; Thomas, M.; Sakai, H.; Smit, E.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib
    Meeting Abstract

    Nadal, E.; Cheema, P. K.; Wu, Y. L.; Ahn, M. J.; Tanizaki, J.; Gharagoozloo, S.; Nizialek, E.; Shi, X.; van der Gronde, T.; Yu, H. A.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Enhancing enrollment to 1L NSCLC trials by allowing 1 prior cycle of standard of care (SOC): SUNRAY-01 experience
    Meeting Abstract

    Hochmair, M. J.; Arbour, K. C.; Negrao, M. V.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Leal, T. A.; Lindsay, C.; Lu, S.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Things you should know about managing ALK plus metastatic NSCLC
    Editorial

    Kris, M. G.; Gainor, J.; Preeshagul, I.; Yu, H. A.
    Oncology (Norwalk) (2025)

    Fulltext@MSK | Save